Funding for this research was provided by:
Kreftforeningen (contract 194751-2017)
Wilhelm Sander-Stiftung (2016.056.1)
Health Research Manchester Biomedical Research Centre (IS-BRC-1215-20007)
Spanish Ministry of Economy and Competitiveness and cofunded by FEDER funds (SAF2015-68016-R))
Text and Data Mining valid from 2019-10-14
Received: 1 June 2019
Accepted: 11 September 2019
First Online: 14 October 2019
Ethics approval and consent to participate
: All reporting centers obtained informed consent for genetic testing and surveillance procedures. De-identified data was exported for the current study. No named registry needing approval was established for the current study.
: Not applicable.
: Toni Seppälä: a co-owner (20%) of Healthfund Finland Oy (educational and health care services in Finland, not related to patients or scope of this manuscript). Travel costs to a scientific meeting by Medtronic Finland.John Burn: a patent for high speed low cost tumor profiling pending to John Burn and QuantuMDx.All others: None declared.